Clinical Trials Logo

Islet Cell Tumor clinical trials

View clinical trials related to Islet Cell Tumor.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT01374451 Completed - Islet Cell Tumor Clinical Trials

Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET

COOPERATE-1
Start date: June 2011
Phase: Phase 2
Study type: Interventional

This study will estimate the treatment effect of everolimus in combination with pasireotide LAR relative to everolimus alone on progression-free survival (PFS) in patients with advanced progressive PNET

NCT ID: NCT00602082 Completed - Clinical trials for Gastrointestinal Carcinoid Tumor

Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors

Start date: August 2005
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as capecitabine, streptozocin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving capecitabine together with streptozocin is more effective with or without cisplatin in treating neuroendocrine tumors. PURPOSE: This randomized phase II trial is studying giving capecitabine together with streptozocin to see how well it works compared with or without cisplatin in treating patients with unresectable or metastatic neuroendocrine tumors.

NCT ID: NCT00434109 Completed - Clinical trials for Neuroendocrine Tumor

Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization

Start date: November 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to decide if a medicine that slows growth of new blood vessels can be give after the embolization procedure to prevent or delay new growth of blood vessels to tumors.

NCT ID: NCT00427349 Completed - Clinical trials for Gastrointestinal Carcinoid Tumor

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Start date: November 7, 2008
Phase: Phase 2
Study type: Interventional

RATIONALE: AMG 706 and octreotide may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well AMG 706 and octreotide work in treating patients with low-grade neuroendocrine tumors.

NCT ID: NCT00416767 Completed - Clinical trials for Gastrointestinal Carcinoid Tumor

Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery

Start date: May 2004
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well combination chemotherapy works as first-line therapy in treating patients with locally advanced or metastatic neuroendocrine tumors of the duodenum or pancreas that cannot be removed by surgery.

NCT ID: NCT00049023 Completed - Sarcoma Clinical Trials

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

Start date: January 2002
Phase: Phase 1
Study type: Interventional

RATIONALE: Radiolabeled octreotide can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells. PURPOSE: This phase I trial is to study the safety and effectiveness of radiolabeled octreotide in treating children who have advanced or refractory solid tumors.

NCT ID: NCT00027638 Completed - Lung Cancer Clinical Trials

Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors

Start date: March 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: Thalidomide may stop the growth of neuroendocrine tumors by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have metastatic neuroendocrine tumors.

NCT ID: NCT00019786 Completed - Colorectal Cancer Clinical Trials

Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases

Start date: August 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells. PURPOSE: This phase II trial is studying how well isolated hepatic perfusion with melphalan works in treating patients with primary unresectable liver cancer or liver metastases.

NCT ID: NCT00017199 Completed - Clinical trials for Gastrointestinal Carcinoid Tumor

PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors

Start date: April 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of PS-341 in treating patients who have metastatic neuroendocrine tumors.

NCT ID: NCT00006368 Completed - Breast Cancer Clinical Trials

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

Start date: January 1998
Phase: Phase 1
Study type: Interventional

RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of yttrium Y 90 SMT 487 in treating patients who have refractory or recurrent cancer.